Search results
Showing 1 to 15 of 659 results for position
this page, you'll find all our position statements relating to technology appraisals. Biosimilar technologies: NICE...
find a list of all our position statements relating to our technology appraisal guidance. Biosimilar technologies: NICE...
Position statement on use of the EQ-5D-5L value set for England (updated October 2019)
Our position on use of the EQ-5D-5L valuation set for England
There are 2 different points of the lifecycle of a NICE Technology Appraisal at which consideration of reference to or inclusion of a biosimilar is...
NICE has been collaborating with NHS England on the Chemotherapy Dose Standardisation initiative which has been developed by the Medicines...
Biosimilar technologies: NICE position statement - information for the public
Biosimilar medicines – NICE's approach A biological medicine is any medicinal product made by or derived from a biological (natural) source, for...
This quality standard covers preventing, assessing and managing pressure ulcers (bed sores) in adults, young people and children. It includes risk assessment and support to prevent pressure ulcers. It applies to all settings, including hospitals, care homes (with and without nursing care) and people’s own homes.
View quality statements for QS89Show all sections
Sections for QS89
- Introduction
- List of quality statements
- Quality statement 1: Pressure ulcer risk assessment in hospitals and care homes with nursing
- Quality statement 2: Pressure ulcer risk assessment by community nursing services
- Quality statement 3: Pressure ulcer risk reassessment
- Quality statement 4: Skin assessment
- Quality statement 5: Advice on repositioning
- Quality statement 6: Help with repositioning
This guideline covers identifying and caring for adults who are malnourished or at risk of malnutrition in hospital or in their own home or a care home. It offers advice on how oral, enteral tube feeding and parenteral nutrition support should be started, administered and stopped. It aims to support healthcare professionals identify malnourished people and help them to choose the most appropriate form of support.
This guideline covers the care of women and their babies during labour and immediately after birth. It focuses on women who give birth between 37 and 42 weeks of pregnancy (‘term’). The guideline helps women to make informed choices about where to have their baby and about their care in labour. It also aims to reduce variation in aspects of care.
View recommendations for NG235Show all sections
Sections for NG235
- Overview
- Recommendations
- Recommendations for research
- Rationale and impact
- Context
- Appendix A: Adverse outcomes for different places of birth
- Appendix B: Outcomes for different places of birth – by BMI at booking
- Appendix C: Outcomes for intravenous remifentanil patient-controlled analgesia (PCA) compared with intramuscular pethidine
This guideline covers a set of principles that can be used to help people change their behaviour. The aim is for practitioners to use these principles to encourage people to adopt a healthier lifestyle by, for example, stopping smoking, adopting a healthy diet and being more physically active.
A quick guide to preventing pressure ulcers for managers of care homes
This guideline covers risk assessment, prevention and treatment in children, young people and adults at risk of, or who have, a pressure ulcer (also known as a bedsore or pressure sore). It aims to reduce the number of pressure ulcers in people admitted to secondary or tertiary care or receiving NHS care in other settings, such as primary and community care and emergency departments.
This quality standard covers care after emergency treatment for suspected anaphylaxis, including assessment and referral to specialist allergy services. It describes high-quality care in priority areas for improvement.
View quality statements for QS119Show all sections
Sections for QS119
- Quality statements
- Quality statement 1: Referral to specialist allergy services after emergency treatment
- Quality statement 2: Education in adrenaline auto-injector use
- Quality statement 3: Specialist assessment for venom immunotherapy
- Quality statement 4 (placeholder): Ongoing training in adrenaline auto-injector use
- Update information
- About this quality standard
This guideline covers the circumstances for inducing labour, methods of induction, assessment, monitoring, pain relief and managing complications. It aims to improve advice and care for pregnant women who are thinking about or having induction of labour.
Evidence-based recommendations on trastuzumab emtansine (Kadcyla) for human epidermal growth factor receptor 2 (HER2)-positive, unresectable, locally advanced or metastatic breast cancer in adults who have had trastuzumab and a taxane.